BioNxt的阿尔茨海默氏病药物减慢了早期患者的认知下降,实现了试验目标,并取得了很大成果。 BioNxt's Alzheimer’s drug slowed cognitive decline in early-stage patients, meeting trial goals with strong results.

BioNxt宣布完成第2阶段的临床试验,以进行新的阿尔茨海默氏病治疗,显示在早期病人的认知下降速度减缓方面大有希望的成果。 BioNxt announced the completion of its Phase 2 clinical trial for a new Alzheimer’s treatment, showing promising results in slowing cognitive decline among early-stage patients. 这次审判涉及美国18个医疗中心的320名参与者,在统计学上记忆和日常运作方面有了显著改善,达到了审判的主要终点。 The trial, involving 320 participants across 18 U.S. medical centers, met its primary endpoint with statistically significant improvements in memory and daily functioning. 该公司计划在今年晚些时候向林业发展局提交数据以供加速核准,并将在2026年初开始第三阶段试验。 The company plans to submit data to the FDA for accelerated approval later this year and will begin Phase 3 trials in early 2026.